Lexicon Pharmaceuticals/$LXRX
1D1W1MYTD1Y5YMAX
Capital at risk
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
- Ticker
- $LXRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 81
- Headquarters
- The Woodlands, United States
- Website
- www.lexpharma.com
LXRX Metrics
BasicAdvanced
$881M
-
-$0.16
1.03
-
Price and volume
Market cap
$881M
Beta
1.03
52-week high
$2.68
52-week low
$1.06
Average daily volume
2.7M
Financial strength
Current ratio
13.367
Quick ratio
13.073
Long term debt to equity
0.33
Total debt to equity
0.339
Interest coverage (TTM)
-6.50%
Profitability
EBITDA (TTM)
-54.023
Gross margin (TTM)
86.02%
Net profit margin (TTM)
-147.38%
Operating margin (TTM)
-131.43%
Revenue per employee (TTM)
$510,000
Management effectiveness
Return on assets (TTM)
-14.32%
Return on equity (TTM)
-40.21%
Valuation
Price to revenue (TTM)
18.68
Price to book
5.05
Price to tangible book (TTM)
6.78
Price to free cash flow (TTM)
-11.92
Free cash flow yield (TTM)
-8.39%
Free cash flow per share (TTM)
-0.166
Growth
Revenue change (TTM)
-29.03%
Earnings per share change (TTM)
-52.32%
3-year revenue growth (CAGR)
367.06%
10-year revenue growth (CAGR)
-12.65%
3-year earnings per share growth (CAGR)
-38.72%
10-year earnings per share growth (CAGR)
-2.65%
What the Analysts think about LXRX
Analyst ratings (Buy, Hold, Sell) for Lexicon Pharmaceuticals stock.
Analyst projections of the future price of Lexicon Pharmaceuticals stock.
Bulls say / Bears say
Under its exclusive license with Novo Nordisk, Lexicon has received $65 million in non-dilutive upfront and development milestone payments for LX9851 and is eligible for up to $1 billion in additional milestones plus tiered royalties, bolstering liquidity without equity issuance (GLOBE NEWSWIRE)
The FDA has deemed data from the STENO1 investigator-initiated study adequate for a New Drug Application resubmission of ZYNQUISTA (sotagliflozin) in type 1 diabetes, with Lexicon targeting a Q4 2026 resubmission, offering a clear pathway to label expansion and U.S. approval (GLOBE NEWSWIRE)
Lexicon narrowed its Q1 2026 net loss to $1.0 million from $25.3 million in Q1 2025, reflecting disciplined capital allocation and the impact of LX9851 licensing revenue, demonstrating improved operational efficiency (GLOBE NEWSWIRE)
Lexicon reported a net loss of $31.8 million in Q2 2026 compared to a net income of $3.3 million in Q2 2025, underscoring ongoing unprofitability and volatility in financial performance (GLOBE NEWSWIRE)
Research and development expenses increased to $17.4 million in Q2 2026 from $15.7 million a year earlier, driven by the costly Phase 3 SONATA-HCM trial, intensifying cash burn and pressure on the balance sheet (GLOBE NEWSWIRE)
Total product revenue was only $0.7 million in Q2 2026, reflecting minimal INPEFA sales and heavy dependence on milestone payments rather than sustainable commercial revenue (GLOBE NEWSWIRE)
Data summarised monthly by Lightyear AI. Last updated on 4 Sept 2026.
LXRX Financial Performance
Revenues and expenses
LXRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
LXRX News
AllArticlesVideos
Funds containing LXRX
Fund name | Fund size | $LXRX weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR MSCI All Country World IM€SPYI | €7.5B | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.